P1 Bacteriophage-Enabled Delivery of CRISPR-Cas9 Antimicrobial Activity Against Shigella flexneri .
Yang W HuanVincenzo TorracaRussell BrownJidapha Fa-ArunSydney L MilesDiego A OyarzúnSerge MostowyBaojun WangPublished in: ACS synthetic biology (2023)
The discovery of clustered, regularly interspaced, short palindromic repeats (CRISPR) and the Cas9 RNA-guided nuclease provides unprecedented opportunities to selectively kill specific populations or species of bacteria. However, the use of CRISPR-Cas9 to clear bacterial infections in vivo is hampered by the inefficient delivery of cas 9 genetic constructs into bacterial cells. Here, we use a broad-host-range P1-derived phagemid to deliver the CRISPR-Cas9 chromosomal-targeting system into Escherichia coli and the dysentery-causing Shigella flexneri to achieve DNA sequence-specific killing of targeted bacterial cells. We show that genetic modification of the helper P1 phage DNA packaging site ( pac ) significantly enhances the purity of packaged phagemid and improves the Cas9-mediated killing of S. flexneri cells. We further demonstrate that P1 phage particles can deliver chromosomal-targeting cas9 phagemids into S. flexneri in vivo using a zebrafish larvae infection model, where they significantly reduce the bacterial load and promote host survival. Our study highlights the potential of combining P1 bacteriophage-based delivery with the CRISPR chromosomal-targeting system to achieve DNA sequence-specific cell lethality and efficient clearance of bacterial infection.
Keyphrases
- crispr cas
- genome editing
- induced apoptosis
- escherichia coli
- cell cycle arrest
- copy number
- circulating tumor
- cancer therapy
- genome wide
- pseudomonas aeruginosa
- cell free
- single molecule
- small molecule
- dendritic cells
- single cell
- gene expression
- cell death
- stem cells
- nucleic acid
- risk assessment
- cell proliferation
- immune response
- multidrug resistant
- regulatory t cells
- human health
- biofilm formation